Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids


  • Study type

  • Study phase

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

  • Site IRB
    • Rochester, Minnesota: 16-008671
    • Jacksonville, Florida: 16-008671
    NCT ID: NCT03317795
    Sponsor Protocol Number: 16-008671

About this study

This is a randomized controlled trial (RCT) to assess the comparative effectiveness of Levonorgestrel Intrauterine System (LNG-IUS) to Tranexamic Acid (TA) for the treatment of heavy menstrual bleeding (HMB) in women with clinically-significant fibroids.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • Premenopausal women ages 25 -50
  • Monthly menses
  • Image-confirmed uterine fibroids of at least 1 cm in size, either submucosal or intramural
  • Seeking treatment for heavy menstrual bleeding following completed clinical evaluation
  • Self-reported heavy menstrual bleeding for three months or longer
  • Completed evaluation for heavy menstrual bleeding within one year of study enrollment
  • Understands the English language for consent and questionnaires
  • Able and willing to provide informed consent

Exclusion Criteria:

  • Class 0 fibroids confirmed by hysteroscopy, saline-infused sonogram, or 3D ultrasound
  • Uterine sounding length ≥ 14 cm
  • Uterine size ≥ 20 weeks gestational size
  • Abnormal endometrial biopsy or incomplete clinical testing to rule out malignancy
  • Needs hormonal contraception, including estrogen-containing medications
  • Venous thromboembolic history, clotting disorder, or strong family history of venous thromboembolic events
  • Breast, uterine, or cervical malignancy
  • Liver disease or liver tumor
  • Pelvic inflammatory disease, gonorrhea or chlamydia infection during the past three months
  • Hemoglobin < 8 mg/dL. For women with hemoglobin 8.0 - 12.0 mg/dL, iron supplement is recommended
  • Serum creatinine ≥ 1.4
  • Current pregnancy or currently lactating

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Shannon Laughlin-Tommaso, M.D.

Open for enrollment

Contact information:

Laura Akhtar CCRP


Jacksonville, Fla.

Mayo Clinic principal investigator

Shannon Laughlin-Tommaso, M.D.

Open for enrollment

Contact information:

Christopher Destephano M.D., M.P.H.


More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer